After the great success of the tyrosine kinase inhibitor Imatinib to treat chronic myeloid leukemia (CML) by blocking the kinase activity of BCR-ABL, the hope was to obtain similar results when treating many cancers where the driver mutation was in the ERK kinase-cascade. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.